Beovu access in India: the CDSCO named-patient pathway
How patients in the Republic of India legally obtain Beovu (brolucizumab-dbll) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Ask about Beovu in India
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Quick orientation
Patients in India access Beovu (brolucizumab-dbll) for neovascular (wet) age-related macular degeneration and diabetic macular edema through the CDSCO named-patient pathway, a Central Drugs Standard Control Organisation-administered mechanism that allows an Indian-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and how to get a written quote.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Reserved for you.
How Beovu reaches patients in India
Beovu (brolucizumab-dbll, a humanised single-chain antibody fragment binding VEGF-A from Novartis, FDA-approved October 2019 for neovascular wet age-related macular degeneration and subsequently for diabetic macular oedema, label resource at accessdata.fda.gov) has had a complex post-marketing safety profile internationally, with the FDA label carrying a warning for retinal vasculitis and retinal vascular occlusion. The Central Drugs Standard Control Organization SUGAM approved-product search at cdscoonline.gov.in should be checked for current registered status at the snapshot date; where Beovu is not stocked at the specific presentation or strength a treating retinal specialist has prescribed, patients access the medicine under the Permission to Import Small Quantities of New Drug for Personal Use, the statutory Form 12-B Permit applied for via Form 12-A under Rules 36 and 36A of the Drugs and Cosmetics Rules 1945 read with the New Drugs and Clinical Trials Rules 2019, pathway page at cdsco.gov.in/Drugs-for-Personal-Use. Applications are filed online through the SUGAM portal at cdscoonline.gov.in/CDSCO/Drugs_Personal. We give you a written timeline estimate for your case before you commit. Where the dispensing hospital is the importer-of-record for an admitted named patient, the parallel Import Licence for Personal Use in CT Form-16 under the New Drugs and Clinical Trials Rules 2019 applies, rules text at cdsco.gov.in/Acts-and-rules/New-Drugs. The prescribing retinal specialist's National Medical Commission registration number, the case summary, and a pro-forma invoice support the file. Form 12-B is single-consignment per shipment cycle.
Where Beovu is dispensed in India
Beovu is administered as a 6 mg intravitreal injection in a sterile vitreoretinal clinic setting following a loading phase then maintenance every 8 to 12 weeks. Indian dispensing routes through vitreoretinal subspecialty programmes at dedicated eye institutes and tertiary ophthalmology services. The dispensing pharmacy releases for same-session injection rather than outpatient home storage.
What Beovu costs in India
Medicine price: quote on request. Every case gets a written custom quote before you commit. Annualised cost depends on the treating retinal specialist's loading and maintenance schedule per the FDA-approved label for wet AMD and diabetic macular oedema; a maintenance interval of every 8 to 12 weeks yields roughly 4 to 6 doses per year after the loading phase. Cost layers stacked on the drug cost include international validated 2 to 8 degree Celsius cold-chain freight, CDSCO permit and customs handling, the vitreoretinal facility's injection-procedure charge, the OCT and FAF baseline and follow-up imaging fees, and the Reserve Meds coordination fee itemised separately on every firm quote. Goods and Services Tax on life-saving medicines sits at 5 percent.
Funding and access barriers for Beovu in India
Funding for anti-VEGF intravitreal therapy in India varies sharply by sector. Medicine price: quote on request. You get a written quote for your case before you commit. Public-sector tertiary eye institutes operate sliding-scale charges. private health insurers cover intravitreal anti-VEGF therapy variably; many plans pay the procedure but cap the drug at the locally registered biosimilar or branded alternative. Coverage of an unregistered named-patient import of Beovu specifically is not the norm and requires case-by-case adjudication, often citing the FDA-labelled indication and the retinal specialist's clinical rationale relative to locally available agents. The National Programme for Control of Blindness at npcbvi.mohfw.gov.in operates a national blindness-prevention infrastructure but does not generally fund individual anti-VEGF agents at originator-brand pricing. Family self-pay through diaspora remittance is a common pattern. The post-marketing retinal vasculitis safety signal has shifted some prescribers toward aflibercept (Eylea), ranibizumab (Lucentis or its biosimilars), or faricimab (Vabysmo) as first-line; named-patient Beovu requests now sit primarily where the retinal specialist has weighed the safety signal against the patient's clinical profile and the longer maintenance interval.
Recent regulatory and access news for Beovu
The CDSCO Notifications feed at cdsco.gov.in/Notifications has not posted a brolucizumab-specific Indian notification over the last 12 months as of 2026-06-01. The US FDA prescribing information for Beovu retains the warning regarding retinal vasculitis and retinal vascular occlusion, with the most current label at accessdata.fda.gov. The European Medicines Agency human medicines portal at ema.europa.eu continues to publish periodic safety updates for the agent. The All India Ophthalmological Society and the Vitreoretinal Society of India have continued retinal vasculitis surveillance reporting through 2025 and 2026 with no India-specific regulatory restriction beyond the labelled warnings observed at the snapshot date.
Where Reserve Meds fits in Beovu cases
Reserve Meds is a US-based digital health company. We do not replace your treating physician, we do not replace CDSCO, and we do not replace your dispensing pharmacy. For Beovu specifically, we orchestrate supply through a US-licensed pharmaceutical wholesale partner, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into India, and give you one point of contact through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.
Operationally, a typical Beovu case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the CDSCO application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the case coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.
Beovu is administered by intravitreal injection in a sterile clinic setting; named-patient files in India document the baseline OCT and FAF imaging, the FDA-labelled dosing schedule for the specific indication (wet AMD, DME, RVO, or DR), and the retinal specialist's intravitreal injection volume. Cold-chain (2 to 8 degrees Celsius) handling is required through the dispensing pharmacy with continuous temperature logging; the dispensing pharmacy releases the medicine for same-session injection at the clinic rather than for outpatient home storage.
Next step
If your Indian physician has prescribed Beovu and you are weighing the cross-border route, the next step is a short intake. We reply within one business day, then send a documentation checklist to your doctor.
Reserved for you.